|
2013 -- H 5372 SUBSTITUTE A | |
|
======= | |
|
LC01079/SUB A | |
|
======= | |
|
STATE OF RHODE ISLAND | |
|
| |
|
IN GENERAL ASSEMBLY | |
|
| |
|
JANUARY SESSION, A.D. 2013 | |
|
| |
|
____________ | |
|
| |
|
H O U S E R E S O L U T I O N | |
|
REQUESTING THE EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES TO | |
|
INVESTIGATE THE FEASIBILITY OF ESTABLISHING A COMPETITIVE BIDDING | |
|
PROCESS FOR GENERIC DRUGS PROVIDED TO RHODE ISLAND MEDICAID | |
|
RECIPIENTS | |
|
|
|
|
|
|
|
Introduced By: Representatives Williams, Marcello, Corvese, Hearn, and Ucci | |
|
Date Introduced: February 12, 2013 | |
|
Referred To: House Finance | |
|
1-1 |
WHEREAS, With every prescription filled with a generic, a consumer receives the same |
|
1-2 |
medicine as the brand name, with the same quality and same result, but at a much lower cost; |
|
1-3 |
WHEREAS, For more than twenty-five (25) years, America's generic pharmaceutical |
|
1-4 |
industry has been providing the food and drug administration "(FDA)" approved generic versions |
|
1-5 |
of brand name medicines at a savings to consumers of thirty percent (30%) to as much as eighty |
|
1-6 |
percent (80%); |
|
1-7 |
WHEREAS, Millions of Medicaid recipients nationwide are using generics to treat a |
|
1-8 |
variety of medical conditions, including infection, heart disease and cancer; |
|
1-9 |
WHEREAS, Generics are rigorously tested by the FDA and must prove that they are the |
|
1-10 |
same medicine with the same active ingredient, strength and dosage as their brand name |
|
1-11 |
counterpart; |
|
1-12 |
WHEREAS, Today, there are thousands of generic drugs available and all are |
|
1-13 |
manufactured and inspected under the same strict quality guidelines as a brand name drug; |
|
1-14 |
WHEREAS, For most brand name products, there are multiple generics available and |
|
1-15 |
these generics can vary greatly in prices; |
|
1-16 |
WHEREAS, While the state Medicaid program has encouraged the use of generic drugs |
|
1-17 |
by Medicaid recipients and thus generated savings for the state, additional savings may be |
|
1-18 |
generated by establishing a competitive bidding process among generic drug manufacturers; now |
|
1-19 |
therefore be it |
|
2-1 |
RESOLVED, That the Rhode Island executive and office of health and human services |
|
2-2 |
shall study the feasibility of requiring all generic manufacturers, whose products are provided to |
|
2-3 |
Rhode Island Medicaid recipients, to engage in a competitive bidding process and make a report |
|
2-4 |
to the chair of the house finance committee on or before May 1, 2014; and be it further |
|
2-5 |
RESOLVED, That the secretary of state be, and hereby is authorized and directed to |
|
2-6 |
transmit a duly certified copy of this resolution to the director of the executive office of health |
|
2-7 |
and human services. |
|
| |
|
2-1 |
======= |
|
2-2 |
LC01079/SUB A |
|
2-3 |
======== |